Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2005 3
2007 5
2008 6
2009 8
2010 13
2011 24
2012 29
2013 27
2014 36
2015 29
2016 26
2017 31
2018 35
2019 36
2020 32
2021 30
2022 31
2023 33
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

397 results

Results by year

Filters applied: . Clear all
Page 1
Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer.
Qin S, Li J, Bai Y, Wang Z, Chen Z, Xu R, Xu J, Zhang H, Chen J, Yuan Y, Liu T, Yang L, Zhong H, Chen D, Shen L, Hao C, Fu D, Cheng Y, Yang J, Wang Q, Qin B, Pan H, Zhang J, Bai X, Zheng Q. Qin S, et al. J Clin Oncol. 2023 Nov 20;41(33):5163-5173. doi: 10.1200/JCO.22.02630. Epub 2023 Aug 30. J Clin Oncol. 2023. PMID: 37647576 Clinical Trial.
PURPOSE: In a phase IIb trial of nimotuzumab plus gemcitabine, substantial clinical benefits were observed in patients with locally advanced or metastatic pancreatic cancer (PC). ...CONCLUSION: In patients with locally advanced or metastatic K-Ras wild-type PC, nimotuzu …
PURPOSE: In a phase IIb trial of nimotuzumab plus gemcitabine, substantial clinical benefits were observed in patients with locally a …
177Lu-nimotuzumab.
Wiwanitkit V. Wiwanitkit V. Nucl Med Biol. 2012 Aug;39(6):891. doi: 10.1016/j.nucmedbio.2012.01.009. Nucl Med Biol. 2012. PMID: 22817873 No abstract available.
Nimotuzumab: beyond the EGFR signaling cascade inhibition.
Mazorra Z, Chao L, Lavastida A, Sanchez B, Ramos M, Iznaga N, Crombet T. Mazorra Z, et al. Semin Oncol. 2018 Jan;45(1-2):18-26. doi: 10.1053/j.seminoncol.2018.04.008. Epub 2018 May 2. Semin Oncol. 2018. PMID: 30318080 Free article. Review.
Recently, new potential mechanisms of action of nimotuzumab involving the activation of the innate and adaptive immune response have been reported. This review summarizes the main properties of nimotuzumab in comparison with other EGFR-specific monoclonal antibodies …
Recently, new potential mechanisms of action of nimotuzumab involving the activation of the innate and adaptive immune response have …
Nimotuzumab in pediatric glioma.
Lam C, Bouffet E, Bartels U. Lam C, et al. Future Oncol. 2009 Nov;5(9):1349-61. doi: 10.2217/fon.09.119. Future Oncol. 2009. PMID: 19903064 Review.
In vitro and in vivo studies have supported the antiproliferative, antiangiogenic, pro-apoptotic and radiosensitizing activities of nimotuzumab. Emerging trials suggest a promising role for nimotuzumab as a therapeutic agent in patients with high-grade gliomas. This …
In vitro and in vivo studies have supported the antiproliferative, antiangiogenic, pro-apoptotic and radiosensitizing activities of nimot …
Nimotuzumab for COVID-19: case series.
Abdo Cuza AA, Ávila JP, Martínez RM, González JJ, Aspuro GP, Gutiérrez Martínez JA, Suzarte MR, Hernández DS, Añé-Kouri AL, Ramos TC. Abdo Cuza AA, et al. Immunotherapy. 2021 Nov 22:10.2217/imt-2021-0269. doi: 10.2217/imt-2021-0269. Online ahead of print. Immunotherapy. 2021. PMID: 34806405 Free PMC article.
Clinical symptoms significantly improved after nimotuzumab administration, and the CT scans at discharge showed major resolution of the lung lesions and no signs of fibrosis. Conclusion: Safe anti-EGFR antibodies like nimotuzumab may modulate COVID-19-associated hyp …
Clinical symptoms significantly improved after nimotuzumab administration, and the CT scans at discharge showed major resolution of t …
EGFR-targeted therapies in the post-genomic era.
Xu MJ, Johnson DE, Grandis JR. Xu MJ, et al. Cancer Metastasis Rev. 2017 Sep;36(3):463-473. doi: 10.1007/s10555-017-9687-8. Cancer Metastasis Rev. 2017. PMID: 28866730 Free PMC article. Review.
The monoclonal antibody cetuximab is a Food and Drug Administration (FDA)-approved EGFR-targeted therapy, yet has exhibited modest benefit in clinical trials. The humanized monoclonal antibody nimotuzumab is also approved for head and neck cancers in Cuba, Argentina, Colom …
The monoclonal antibody cetuximab is a Food and Drug Administration (FDA)-approved EGFR-targeted therapy, yet has exhibited modest benefit i …
Anti-EGFR therapies in nasopharyngeal carcinoma.
Chen X, Liang R, Zhu X. Chen X, et al. Biomed Pharmacother. 2020 Nov;131:110649. doi: 10.1016/j.biopha.2020.110649. Epub 2020 Aug 21. Biomed Pharmacother. 2020. PMID: 32836074 Free article. Review.
(90)Y-DOTA-Nimotuzumab: Synthesis of a Promising beta- Radiopharmaceutical.
Scotognella T, Maccora D, Bruno I, Chinol M, Castagnola M, Collamati F, Mancini-Terraciano C, Morganti S, Bocci V, Camillocci ES, Rotili D, Cartoni A, Fratoddi I, Marini F, Venditti I, Faccini R, Giordano A. Scotognella T, et al. Curr Radiopharm. 2022;15(1):32-39. doi: 10.2174/1874471013999210104220031. Curr Radiopharm. 2022. PMID: 33397277
This study aimed to label the conjugate DOTA-nimotuzumab with yttrium-90, in order to provide a beta- emitting radioimmunoconjugate ((90)Y-DOTA-nimotuzumab) potentially useful to assess the feasibility of a new radio-guided surgery approach. METHODS: The synthesis o …
This study aimed to label the conjugate DOTA-nimotuzumab with yttrium-90, in order to provide a beta- emitting radioimmunoconjugate ( …
Preclinical Evaluation of (111)In-Labeled PEGylated Maytansine Nimotuzumab Drug Conjugates in EGFR-Positive Cancer Models.
Hartimath SV, Alizadeh E, Solomon VR, Chekol R, Bernhard W, Hill W, Parada AC, Barreto K, Geyer CR, Fonge H. Hartimath SV, et al. J Nucl Med. 2019 Aug;60(8):1103-1110. doi: 10.2967/jnumed.118.220095. Epub 2019 Jan 17. J Nucl Med. 2019. PMID: 30655327 Free article.
The in vitro binding and internalization rates of (111)In-nimotuzumab, (111)In-nimotuzumab-PEG(6)-DM1-Low, and (111)In-nimotuzumab-PEG(6)-DM1-High were characterized. ...Tumor-to-background ratios for (111)In-nimotuzumab and (111)In-nimotuzumab- …
The in vitro binding and internalization rates of (111)In-nimotuzumab, (111)In-nimotuzumab-PEG(6)-DM1-Low, and (111)In-nimo …
Profile of nimotuzumab in the treatment of high-grade glioma.
Yang QY, Guo CC, Chen ZP. Yang QY, et al. Onco Targets Ther. 2015 Apr 13;8:819-25. doi: 10.2147/OTT.S60032. eCollection 2015. Onco Targets Ther. 2015. PMID: 25926743 Free PMC article. Review.
In conclusion, nimotuzumab is a very well-tolerated drug with acceptable toxicity, and it may have promising value in the combination treatment. As a result, multiple center randomized controlled Phase III clinical trials need to be conducted to confirm the efficacy and to …
In conclusion, nimotuzumab is a very well-tolerated drug with acceptable toxicity, and it may have promising value in the combination …
397 results